Exploring the pharmacological mechanism of Tongluo Qingnao formula in treating acute ischemic stroke: A combined approach of network pharmacology, molecular docking and experimental evidences

Introduction: Tongluo Qingnao (TLQN) Formula is a patent Traditional Chinese Medicine injection designed for the treatment of Acute Ischemic Stroke (AIS) and associated complications. Previous researches had shown promising potential of TLQN in treating ischemic brain edema. This study aimed to reve...

Full description

Saved in:
Bibliographic Details
Main Authors: Feng Li, Yilei Dong, Guangrui Wang, Zishan Huang, Wenting Song, Xiaoyu Zheng, Peng Zhang, Mingjiang Yao
Format: Article
Language:English
Published: Elsevier 2024-12-01
Series:Pharmacological Research - Modern Chinese Medicine
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S2667142524001921
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850053881842630656
author Feng Li
Yilei Dong
Guangrui Wang
Zishan Huang
Wenting Song
Xiaoyu Zheng
Peng Zhang
Mingjiang Yao
author_facet Feng Li
Yilei Dong
Guangrui Wang
Zishan Huang
Wenting Song
Xiaoyu Zheng
Peng Zhang
Mingjiang Yao
author_sort Feng Li
collection DOAJ
description Introduction: Tongluo Qingnao (TLQN) Formula is a patent Traditional Chinese Medicine injection designed for the treatment of Acute Ischemic Stroke (AIS) and associated complications. Previous researches had shown promising potential of TLQN in treating ischemic brain edema. This study aimed to reveal specific mechanisms of TLQN in treating AIS by bioinformatics analysis and following confirmatory experiments. Methods: HPLC was used to analyze the active ingredients of TLQN. Network Pharmacology and Molecular Docking were introduced to screen treatment targets and pathways. And then middle cerebral artery occlusion and reperfusion (MCAO/R) model was established in rats to verify the therapeutic effect of TLQN in neurological deficit score, cerebral infarction size, HE staining, TUNEL staining, and proteins expression related to inflammation, apoptosis and the PI3K-AKT signaling pathway. Results: Seven main active ingredients were contained in TLQN. Network pharmacology identified IL-6 and IL-1β as the key targets, and PI3K-AKT as the critical pathway. Molecular Docking analysis indicated that the constituents of TLQN demonstrated a high affinity for crucial targets. TLQN could significantly reduce neurological deficits, pathological lesions and apoptosis caused by AIS. Western blotting results indicated that TLQN can activate the PI3K-AKT signaling pathway, inhibit the expression of pro-apoptotic proteins bax, Caspase-3 and inflammatory factors IL-6, IL-1β. Discussion: TLQN has a therapeutic effect on AIS, and these results highlight the therapeutic effects of TLQN on AIS by activating PI3K-AKT signaling pathway to inhibit inflammation and apoptosis.
format Article
id doaj-art-e4b360d90c6345148144307a2e99b8a7
institution DOAJ
issn 2667-1425
language English
publishDate 2024-12-01
publisher Elsevier
record_format Article
series Pharmacological Research - Modern Chinese Medicine
spelling doaj-art-e4b360d90c6345148144307a2e99b8a72025-08-20T02:52:25ZengElsevierPharmacological Research - Modern Chinese Medicine2667-14252024-12-011310055010.1016/j.prmcm.2024.100550Exploring the pharmacological mechanism of Tongluo Qingnao formula in treating acute ischemic stroke: A combined approach of network pharmacology, molecular docking and experimental evidencesFeng Li0Yilei Dong1Guangrui Wang2Zishan Huang3Wenting Song4Xiaoyu Zheng5Peng Zhang6Mingjiang Yao7Institute of Basic Medical Sciences, Xiyuan Hospital of China Academy of Chinese Medical Sciences, No.1 Xiyuan Caochang, Haidian District, Beijing 100091, PR China; Key Laboratory of Pharmacology of Chinese Materia Medica, Beijing 100091, PR ChinaInstitute of Basic Medical Sciences, Xiyuan Hospital of China Academy of Chinese Medical Sciences, No.1 Xiyuan Caochang, Haidian District, Beijing 100091, PR China; Key Laboratory of Pharmacology of Chinese Materia Medica, Beijing 100091, PR ChinaInstitute of Basic Medical Sciences, Xiyuan Hospital of China Academy of Chinese Medical Sciences, No.1 Xiyuan Caochang, Haidian District, Beijing 100091, PR China; Key Laboratory of Pharmacology of Chinese Materia Medica, Beijing 100091, PR ChinaInstitute of Basic Medical Sciences, Xiyuan Hospital of China Academy of Chinese Medical Sciences, No.1 Xiyuan Caochang, Haidian District, Beijing 100091, PR China; Key Laboratory of Pharmacology of Chinese Materia Medica, Beijing 100091, PR China; Research Institute of Traditional Chinese Medicine(TCM) of Guangdong Pharmaceutical University, Guangzhou, Guangdong 510006, PR ChinaInstitute of Basic Medical Sciences, Xiyuan Hospital of China Academy of Chinese Medical Sciences, No.1 Xiyuan Caochang, Haidian District, Beijing 100091, PR China; Key Laboratory of Pharmacology of Chinese Materia Medica, Beijing 100091, PR ChinaInstitute of Basic Medical Sciences, Xiyuan Hospital of China Academy of Chinese Medical Sciences, No.1 Xiyuan Caochang, Haidian District, Beijing 100091, PR China; Key Laboratory of Pharmacology of Chinese Materia Medica, Beijing 100091, PR ChinaInstitute of Basic Medical Sciences, Xiyuan Hospital of China Academy of Chinese Medical Sciences, No.1 Xiyuan Caochang, Haidian District, Beijing 100091, PR China; Key Laboratory of Pharmacology of Chinese Materia Medica, Beijing 100091, PR ChinaInstitute of Basic Medical Sciences, Xiyuan Hospital of China Academy of Chinese Medical Sciences, No.1 Xiyuan Caochang, Haidian District, Beijing 100091, PR China; Key Laboratory of Pharmacology of Chinese Materia Medica, Beijing 100091, PR China; Corresponding author at: Institute of Basic Medical Sciences, Xiyuan Hospital of China Academy of Chinese Medical Sciences, No.1 Xiyuan Caochang, Haidian District, Beijing 100091, PR China.Introduction: Tongluo Qingnao (TLQN) Formula is a patent Traditional Chinese Medicine injection designed for the treatment of Acute Ischemic Stroke (AIS) and associated complications. Previous researches had shown promising potential of TLQN in treating ischemic brain edema. This study aimed to reveal specific mechanisms of TLQN in treating AIS by bioinformatics analysis and following confirmatory experiments. Methods: HPLC was used to analyze the active ingredients of TLQN. Network Pharmacology and Molecular Docking were introduced to screen treatment targets and pathways. And then middle cerebral artery occlusion and reperfusion (MCAO/R) model was established in rats to verify the therapeutic effect of TLQN in neurological deficit score, cerebral infarction size, HE staining, TUNEL staining, and proteins expression related to inflammation, apoptosis and the PI3K-AKT signaling pathway. Results: Seven main active ingredients were contained in TLQN. Network pharmacology identified IL-6 and IL-1β as the key targets, and PI3K-AKT as the critical pathway. Molecular Docking analysis indicated that the constituents of TLQN demonstrated a high affinity for crucial targets. TLQN could significantly reduce neurological deficits, pathological lesions and apoptosis caused by AIS. Western blotting results indicated that TLQN can activate the PI3K-AKT signaling pathway, inhibit the expression of pro-apoptotic proteins bax, Caspase-3 and inflammatory factors IL-6, IL-1β. Discussion: TLQN has a therapeutic effect on AIS, and these results highlight the therapeutic effects of TLQN on AIS by activating PI3K-AKT signaling pathway to inhibit inflammation and apoptosis.http://www.sciencedirect.com/science/article/pii/S2667142524001921Tongluo qingnao formulaNetwork pharmacologyMolecular dockingAcute Ischemic StrokePI3K-AKT signaling pathway
spellingShingle Feng Li
Yilei Dong
Guangrui Wang
Zishan Huang
Wenting Song
Xiaoyu Zheng
Peng Zhang
Mingjiang Yao
Exploring the pharmacological mechanism of Tongluo Qingnao formula in treating acute ischemic stroke: A combined approach of network pharmacology, molecular docking and experimental evidences
Pharmacological Research - Modern Chinese Medicine
Tongluo qingnao formula
Network pharmacology
Molecular docking
Acute Ischemic Stroke
PI3K-AKT signaling pathway
title Exploring the pharmacological mechanism of Tongluo Qingnao formula in treating acute ischemic stroke: A combined approach of network pharmacology, molecular docking and experimental evidences
title_full Exploring the pharmacological mechanism of Tongluo Qingnao formula in treating acute ischemic stroke: A combined approach of network pharmacology, molecular docking and experimental evidences
title_fullStr Exploring the pharmacological mechanism of Tongluo Qingnao formula in treating acute ischemic stroke: A combined approach of network pharmacology, molecular docking and experimental evidences
title_full_unstemmed Exploring the pharmacological mechanism of Tongluo Qingnao formula in treating acute ischemic stroke: A combined approach of network pharmacology, molecular docking and experimental evidences
title_short Exploring the pharmacological mechanism of Tongluo Qingnao formula in treating acute ischemic stroke: A combined approach of network pharmacology, molecular docking and experimental evidences
title_sort exploring the pharmacological mechanism of tongluo qingnao formula in treating acute ischemic stroke a combined approach of network pharmacology molecular docking and experimental evidences
topic Tongluo qingnao formula
Network pharmacology
Molecular docking
Acute Ischemic Stroke
PI3K-AKT signaling pathway
url http://www.sciencedirect.com/science/article/pii/S2667142524001921
work_keys_str_mv AT fengli exploringthepharmacologicalmechanismoftongluoqingnaoformulaintreatingacuteischemicstrokeacombinedapproachofnetworkpharmacologymoleculardockingandexperimentalevidences
AT yileidong exploringthepharmacologicalmechanismoftongluoqingnaoformulaintreatingacuteischemicstrokeacombinedapproachofnetworkpharmacologymoleculardockingandexperimentalevidences
AT guangruiwang exploringthepharmacologicalmechanismoftongluoqingnaoformulaintreatingacuteischemicstrokeacombinedapproachofnetworkpharmacologymoleculardockingandexperimentalevidences
AT zishanhuang exploringthepharmacologicalmechanismoftongluoqingnaoformulaintreatingacuteischemicstrokeacombinedapproachofnetworkpharmacologymoleculardockingandexperimentalevidences
AT wentingsong exploringthepharmacologicalmechanismoftongluoqingnaoformulaintreatingacuteischemicstrokeacombinedapproachofnetworkpharmacologymoleculardockingandexperimentalevidences
AT xiaoyuzheng exploringthepharmacologicalmechanismoftongluoqingnaoformulaintreatingacuteischemicstrokeacombinedapproachofnetworkpharmacologymoleculardockingandexperimentalevidences
AT pengzhang exploringthepharmacologicalmechanismoftongluoqingnaoformulaintreatingacuteischemicstrokeacombinedapproachofnetworkpharmacologymoleculardockingandexperimentalevidences
AT mingjiangyao exploringthepharmacologicalmechanismoftongluoqingnaoformulaintreatingacuteischemicstrokeacombinedapproachofnetworkpharmacologymoleculardockingandexperimentalevidences